These innovative molecules represent a significant advancement in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://aliviagpcx990605.bloggosite.com/46665765/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide